Recruiting × Granulocyte Colony-Stimulating Factor × Other hematologic neoplasm × Clear all Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
116 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Phase 1 Recruiting
20 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Phase 1 Recruiting
30 enrolled
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Phase 2 Recruiting
33 enrolled
ABCD-NK
Phase 1/2 Recruiting
68 enrolled
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Phase 1 Recruiting
60 enrolled
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
171 enrolled
EPOCH
Recruiting
45 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Phase 1/2 Recruiting
36 enrolled
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
270 enrolled
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Phase 2 Recruiting
39 enrolled
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3 Recruiting
324 enrolled
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 2 Recruiting
66 enrolled
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Phase 2 Recruiting
20 enrolled
VHAG in Treating R/R T-ALL/LBL
Phase 2 Recruiting
50 enrolled
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3 Recruiting
50 enrolled
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Phase 2 Recruiting
50 enrolled
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
Phase NA Recruiting
50 enrolled
SCCLG-M5
Phase 2/3 Recruiting
43 enrolled
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
Phase NA Recruiting
100 enrolled